glp-1 gip What is and GIP? Dual-action weight loss (UK) Frontiers | Clinical perspectives on
Description
Maybe the drink feels a stronger
investigated the synergistic effects of MSTN inhibitors and GLP-1 agonists by administering apitegromab in combination with semaglutide, a GLP-1 agonist, and tirzepatide, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide, in patients with obesity (NCT06445075)
Importantly, semglutides approval for MASH marks a watershed moment as it is the second ever MASH-specific therapy to be approved, and the first GLP-1 receptor antagonist, giving it momentum to significantly disrupt the MASH treatment market
Ozempic is approved for type 2 diabetes, while Wegovy is specifically approved for weight loss
